

## EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	2944	((544/319) or (514/269)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2007/09/30 22:06

NPL Search Notes

Printable History

Search	Results
(pde9a and concentration) AND (pde9a and perception) [All Sources(- All Sciences -)]	5
pde9a and concentration [All Sources(- All Sciences -)]	63
pde9a and perception [All Sources(- All Sciences -)]	5
	CLOSE

Copyright © 2007 Elsevier B.V. All rights reserved.  
ScienceDirect® is a registered trademark of Elsevier B.V.

7 9 10 12 13 15 16 19 25 26

1 2 3 4 5 6 27 28 29 30 31 32

2-12 4-13 7-9 12-25

1-2 1-6 2-3 3-4 4-5 5-6 27-28 27-32 28-29 29-30 30-31 31-32

1-2 1-6 2-3 3-4 4-5 4-13 5-6 7-9 12-25

2-12

27-28 27-32 28-29 29-30 30-31 31-32

containing 1 : 27 :

**G2:[\*4],[\*5]**

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS8:Atom 9:CLASS10:CLASS11:Atom 12:CLASS13:CLASS  
15:CLASS16:Atom 19:Atom 25:CLASS26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom 32:Atom

15:

Saturation : Saturated  
16:  
Saturation : Saturated  
19:  
Saturation : Saturated  
Number of Hetero Atoms : Exactly 1  
Type of Ring System : Monocyclic  
26:  
Saturation : Unsaturated

Element Count :


Node 15: Limited  
C,C1-9

Node 16: Limited  
C,C3-8

Node 19: Limited  
C,C4-5  
O,O1  
N,N0  
S,S0

=&gt;

Uploading C:\Program Files\Stnexp\Queries\10559954.str



chain nodes :

7 9 10 12 13 15 16 19 25 26

ring nodes :

1 2 3 4 5 6 27 28 29 30 31 32

chain bonds :

2-12 4-13 7-9 12-25

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 27-28 27-32 28-29 29-30 30-31 31-32

exact/norm bonds :

1-2 1-6 2-3 3-4 4-5 4-13 5-6 7-9 12-25

exact bonds :

2-12

normalized bonds :

27-28 27-32 28-29 29-30 30-31 31-32

isolated ring systems :

containing 1 : 27 :

G1:[\*1],[\*2],[\*3]

G2:[\*4],[\*5]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:CLASS 10:CLASS  
 11:Atom 12:CLASS 13:CLASS 15:CLASS 16:Atom 19:Atom 25:CLASS 26:Atom 27:Atom  
 28:Atom 29:Atom 30:Atom 31:Atom 32:Atom

Generic attributes :

15:

10/559,954

Saturation : Saturated  
16:  
Saturation : Saturated  
19:  
Saturation : Saturated  
Number of Hetero Atoms : Exactly 1  
Type of Ring System : Monocyclic  
26:  
Saturation : Unsaturated

Element Count :  
Node 15: Limited  
C,C1-9

Node 16: Limited  
C,C3-8

Node 19: Limited  
C,C4-5  
O,O1  
N,N0  
S,S0

L1 STRUCTURE UPLOADED

=> d l1  
L1 HAS NO ANSWERS  
L1 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam  
SAMPLE SEARCH INITIATED 21:09:16 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 282 TO ITERATE

100.0% PROCESSED 282 ITERATIONS 2 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 4633 TO 6647  
PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1

=> => s l1 sss ful  
FULL SEARCH INITIATED 21:09:44 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 5551 TO ITERATE

100.0% PROCESSED 5551 ITERATIONS 54 ANSWERS  
SEARCH TIME: 00.00.01

10/559,954

L3            54 SEA SSS FUL L1

=> => s 13

L4            1 L3

=> d 14 bib,ab,hitstr

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2004:1154682 CAPLUS  
 DN 142:93840  
 TI Preparation of 6-arylamino-5-cyano-4-pyrimidinones as PDE9A inhibitors for the treatment of Alzheimer's disease  
 IN Hendrix, Martin; Baerfacker, Lars; Beyreuther, Bettina; Ebert, Ulrich; Erb, Christina; Hafner, Frank-Thorsten; Heckroth, Heike; Liu, Yan-Hong; Schauss, Dagmar; Tersteegen, Adrian; Van Der Staay, Franz-Josef; Van Kampen, Marja  
 PA Bayer Healthcare AG, Germany  
 SO PCT Int. Appl., 63 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA German  
 FAN.CNT 1

Appl.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004113306	A1	20041229	WO 2004-EP6477	20040616
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10328479	A1	20050113	DE 2003-10328479	20030625
AU 2004249392	A1	20041229	AU 2004-249392	20040616
CA 2530461	A1	20041229	CA 2004-2530461	20040616
EP 1644339	A1	20060412	EP 2004-739944	20040616
R: DE, ES, FR, GB, IT				
CN 1835929	A	20060920	CN 2004-80023392	20040616
JP 2007506662	T	20070322	JP 2006-515952	20040616
MX 2005PA13874	A	20060706	MX 2005-PA13874	20051216
US 2007105881	A1	20070510	US 2006-559954	20060928
PRAI DE 2003-10328479	A	20030625		
WO 2004-EP6477	W	20040616		
OS MARPAT 142:93840				

AB Title compds. I [A = (un)substituted alkyl, cycloalkyl, tetrahydrofuryl, etc.; B = (un)substituted Ph, heteroaryl] and their pharmaceutically acceptable salts were prepared For example, condensation-cyclization of 1-cyclopentylacetamidine hydrochloride and (methylsulfanyl)propenoate II, e.g., prepared from 4-fluoroaniline and Me 3,3-bis(methylthio)-2-cyanoacrylate, afforded cyanopyrimidinone III in 46% yield. In phosphodiesterase 9A (PDE9A) inhibition assays, 5-examples of compds. I exhibited IC50 values ranging from 52-87 nM, e.g., the IC50 value of cyanopyrimidinone III was 75 nM. Compds. I are claimed to be useful for the treatment of Alzheimer's disease.

IT 816468-96-9P 816468-97-0P 816468-98-1P  
 816468-99-2P 816469-00-8P 816469-01-9P  
 816469-02-0P 816469-03-1P 816469-04-2P  
 816469-05-3P 816469-06-4P 816469-07-5P  
 816469-08-6P 816469-09-7P 816469-10-0P  
 816469-11-1P 816469-12-2P 816469-13-3P  
 816469-14-4P 816469-15-5P 816469-16-6P  
 816469-17-7P 816469-18-8P 816469-19-9P  
 816469-20-2P 816469-21-3P 816469-22-4P




816469-23-5P 816469-24-6P 816469-25-7P  
 816469-26-8P 816469-27-9P 816469-28-0P  
 816469-29-1P 816469-30-4P 816469-31-5P  
 816469-32-6P 816469-33-7P 816469-38-2P  
 816469-39-3P 816469-40-6P 816469-41-7P  
 816469-42-8P 816469-43-9P 816469-44-0P  
 816469-45-1P 816469-46-2P 816469-47-3P  
 816469-48-4P 816469-49-5P 816469-50-8P  
 816469-51-9P 816469-52-0P 816469-53-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of arylaminocyanopyrimidinones as PDE9A inhibitors for the  
 treatment of Alzheimer's disease)


RN 816468-96-9 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-6-[(4-fluorophenyl)amino]-  
 1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)




RN 816468-97-0 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-1,4-dihydro-6-[(4-methyl-3-pyridinyl)amino]-4-oxo- (9CI) (CA INDEX NAME)




RN 816468-98-1 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(cyclohexylmethyl)-1,4-dihydro-6-[(4-methyl-3-pyridinyl)amino]-4-oxo- (9CI) (CA INDEX NAME)




RN 816468-99-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-6-[(3-fluorophenyl)amino]-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)




RN 816469-00-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 6-[(3-chlorophenyl)amino]-2-(cyclopentylmethyl)-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)




RN 816469-01-9 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-1,4-dihydro-6-[(3-methoxyphenyl)amino]-4-oxo- (9CI) (CA INDEX NAME)




RN 816469-02-0 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-6-[(3-fluoro-2-methylphenyl)amino]-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)




RN 816469-03-1 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-6-[(2,5-dimethylphenyl)amino]-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)




RN 816469-04-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-1,4-dihydro-6-[(2-methoxyphenyl)amino]-4-oxo- (9CI) (CA INDEX NAME)




RN 816469-05-3 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-6-[(4-fluoro-2-methylphenyl)amino]-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)




RN 816469-06-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-1,4-dihydro-6-[(2-methylphenyl)amino]-4-oxo- (9CI) (CA INDEX NAME)




RN 816469-07-5 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-1,4-dihydro-4-oxo-6-[(2-propylphenyl)amino]- (9CI) (CA INDEX NAME)




RN 816469-08-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-1,4-dihydro-4-oxo-6-(3-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 816469-09-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,4-dihydro-2-(2-methylbutyl)-6-[(2-methylphenyl)amino]-4-oxo- (9CI) (CA INDEX NAME)




RN 816469-10-0 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,4-dihydro-2-[(2S)-2-methylbutyl]-6-[(2-methylphenyl)amino]-4-oxo- (9CI) (CA INDEX NAME)

methylphenyl)amino]-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 816469-11-1 CAPLUS


CN 5-Pyrimidinecarbonitrile, 6-[(5-fluoro-2-methylphenyl)amino]-1,4-dihydro-2-[(2S)-2-methylbutyl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 816469-12-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-6-[(2-fluorophenyl)amino]-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)




RN 816469-13-3 CAPLUS

CN 5-Pyrimidinecarbonitrile, 6-[(2-chlorophenyl)amino]-2-(cyclopentylmethyl)-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)




RN 816469-14-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-1,4-dihydro-4-oxo-6-(phenylamino)- (9CI) (CA INDEX NAME)




RN 816469-15-5 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-1,4-dihydro-6-[(2-methyl-3-pyridinyl)amino]-4-oxo- (9CI) (CA INDEX NAME)




RN 816469-16-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-1,4-dihydro-6-[(2-hydroxyphenyl)amino]-4-oxo- (9CI) (CA INDEX NAME)




RN 816469-17-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-6-[(5-fluoro-2-methylphenyl)amino]-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)




RN 816469-18-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-1,4-dihydro-4-oxo-6-[[3-(trifluoromethyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 816469-19-9 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-6-[[4-(dimethylamino)phenyl]amino]-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)




RN 816469-20-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-1,4-dihydro-6-[[4-methoxyphenyl]amino]-4-oxo- (9CI) (CA INDEX NAME)




RN 816469-21-3 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-1,4-dihydro-6-[[4-methylphenyl]amino]-4-oxo- (9CI) (CA INDEX NAME)




RN 816469-22-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,4-dihydro-2-(2-methylbutyl)-6-[(4-methyl-3-pyridinyl)amino]-4-oxo- (9CI) (CA INDEX NAME)



RN 816469-23-5 CAPLUS


CN 5-Pyrimidinecarbonitrile, 6-[(3-fluoro-2-methylphenyl)amino]-1,4-dihydro-2-(2-methylbutyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 816469-24-6 CAPLUS


CN 5-Pyrimidinecarbonitrile, 2-(cyclohexylmethyl)-6-[(2-fluorophenyl)amino]-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)






RN 816469-25-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(cyclohexylmethyl)-6-[(5-fluoro-2-methylphenyl)amino]-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)




RN 816469-26-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(cyclohexylmethyl)-6-[(3-fluoro-2-methylphenyl)amino]-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)




RN 816469-27-9 CAPLUS


CN 5-Pyrimidinecarbonitrile, 6-[(2-chlorophenyl)amino]-2-(cyclohexylmethyl)-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)




RN 816469-28-0 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-(cyclohexylmethyl)-1,4-dihydro-4-oxo-6-(phenylamino)- (9CI) (CA INDEX NAME)



RN 816469-29-1 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-(cyclohexylmethyl)-1,4-dihydro-6-[(2-methoxyphenyl)amino]-4-oxo- (9CI) (CA INDEX NAME)




RN 816469-30-4 CAPLUS  
 CN 5-Pyrimidinecarbonitrile, 2-(cyclohexylmethyl)-1,4-dihydro-6-[(2-methylphenyl)amino]-4-oxo- (9CI) (CA INDEX NAME)




RN 816469-31-5 CAPLUS

CN 5-Pyrimidinecarbonitrile, 6-[(5-acetyl-2-methyl-3-thienyl)amino]-2-(cyclopentylmethyl)-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)




RN 816469-32-6 CAPLUS

CN 3-Thiophenecarboxylic acid, 4-[[5-cyano-2-(cyclopentylmethyl)-1,6-dihydro-6-oxo-4-pyrimidinyl]amino]-, methyl ester (CA INDEX NAME)




RN 816469-33-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 6-[(2-cyano-3-thienyl)amino]-2-(cyclopentylmethyl)-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)




RN 816469-38-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 6-[(5-fluoro-2-methylphenyl)amino]-1,4-dihydro-2-(2-methylbutyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 816469-39-3 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-1,4-dihydro-6-[(2-methoxy-4-methylphenyl)amino]-4-oxo- (9CI) (CA INDEX NAME)




RN 816469-40-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-6-[(2,3-dimethylphenyl)amino]-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)




RN 816469-41-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-1,4-dihydro-6-[[2-(1-methylethyl)phenyl]amino]-4-oxo- (9CI) (CA INDEX NAME)




RN 816469-42-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-6-[(2,4-dimethoxyphenyl)amino]-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)




RN 816469-43-9 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-1,4-dihydro-6-[(2-methoxy-5-methylphenyl)amino]-4-oxo- (9CI) (CA INDEX NAME)




RN 816469-44-0 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-6-[(2,5-dimethoxyphenyl)amino]-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)




RN 816469-45-1 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(cyclopentylmethyl)-1,4-dihydro-6-[(2-methoxy-6-methylphenyl)amino]-4-oxo- (9CI) (CA INDEX NAME)




RN 816469-46-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,4-dihydro-6-[(2-methoxy-5-methylphenyl)amino]-2-(2-methylbutyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 816469-47-3 CAPLUS

CN 5-Pyrimidinecarbonitrile, 6-[(2,4-dimethoxyphenyl)amino]-1,4-dihydro-2-(2-methylbutyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 816469-48-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 6-[(2-chlorophenyl)amino]-1,4-dihydro-2-(2-methylbutyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 816469-49-5 CAPLUS

CN 5-Pyrimidinecarbonitrile, 6-[(2,3-dimethylphenyl)amino]-1,4-dihydro-2-(2-methylbutyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 816469-50-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,4-dihydro-2-(2-methylbutyl)-6-[[2-(1-methylethyl)phenyl]amino]-4-oxo- (9CI) (CA INDEX NAME)




RN 816469-51-9 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,4-dihydro-6-[(2-methoxy-6-methylphenyl)amino]-2-(2-methylbutyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 816469-52-0 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-(2-ethylbutyl)-1,4-dihydro-6-[(2-methylphenyl)amino]-4-oxo- (9CI) (CA INDEX NAME)



RN 816469-53-1 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,4-dihydro-2-(3-methylbutyl)-6-[(2-methylphenyl)amino]-4-oxo- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



10/559,954

=> log y

COST IN U.S. DOLLARS

SINCE FILE  
ENTRY

TOTAL  
SESSION

FULL ESTIMATED COST

5.74

178.50

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE  
ENTRY

TOTAL  
SESSION

CA SUBSCRIBER PRICE

-0.78

-0.78

STN INTERNATIONAL LOGOFF AT 21:10:11 ON 30 SEP 2007